PTEN and cancer: While there is insufficient data to demonstrate the long-term benefits and patient outcomes as a result of incorporated genomic sequencing in patients with PTPR, we do know that the immediate impact of identifying a PTEN germline pathogenic variant has resulted in genetic testing in immediate family members and an awareness and vigilance to screen sooner and more frequently for cancer.